Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALLURION TECHNOLOGIES, INC.ALUR · Entity 8577 | Director | October 03, 2025 | December 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALLURION TECHNOLOGIES, INC.
Report date October 03, 2025 · Filed December 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,814 |
Reported balance
After 2025-10-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-03 · Gift · Disposed 604 · Balance 3,814 F1: On January 3, 2025, the Issuer effected a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share (the "Reverse Stock Split"). The number of securities reported herein have been adjusted to reflect the Reverse Stock Split. |
| Common StockSEC Table I · non-derivative | Direct | 1,206 |
Reported balance
After 2025-11-26 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-11-26 · Gift · Disposed 2,608 · Balance 1,206 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Last balance in matching sequence
After 2025-12-04 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 2 · 2025-10-03 · Gift · Acquired 604 · Balance 604 F2: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Row 4 · 2025-11-26 · Gift · Acquired 2,608 · Balance 3,212 F2: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Row 5 · 2025-12-03 · Sale · Disposed 1,606 · Balance 1,606 F2: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Row 6 · 2025-12-04 · Sale · Disposed 1,606 · Balance 0 F2: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 3, 2025, the Issuer effected a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share (the "Reverse Stock Split"). The number of securities reported herein have been adjusted to reflect the Reverse Stock Split.
F2: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CYNOSURE INC
Report date March 22, 2017 · Filed March 24, 2017
Section 16 reporting ended · disclosed 2017-03-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-03-22 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2017-03-22 · Other · Disposed 38,625 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration"). Row 2 · 2017-03-22 · Grant · Acquired 58,176 · Balance 58,176 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Row 3 · 2017-03-22 · Disposition to issuer · Disposed 58,176 · Balance 0 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Row 4 · 2017-03-22 · Grant · Acquired 62,893 · Balance 62,893 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Row 5 · 2017-03-22 · Disposition to issuer · Disposed 62,893 · Balance 0 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Row 6 · 2017-03-22 · Grant · Acquired 73,754 · Balance 73,754 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Row 7 · 2017-03-22 · Disposition to issuer · Disposed 73,754 · Balance 0 F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $29.40 · Expires 2024-02-13 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-03-22 · Disposition to issuer · Disposed 12,062 · Balance 0 F3: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $30.51 · Expires 2025-02-11 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-03-22 · Disposition to issuer · Disposed 21,108 · Balance 0 F4: Includes 16,887 shares that were unvested prior to the Effective Time and 4,221 shares that were vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-02-11 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-03-22 · Disposition to issuer · Disposed 11,088 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-03-22 · Disposition to issuer · Disposed 16,875 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-02-08 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-03-22 · Disposition to issuer · Disposed 30,172 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration").
F2: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share.
F3: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option.
F4: Includes 16,887 shares that were unvested prior to the Effective Time and 4,221 shares that were vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option.
F5: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock.
F6: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | SaleCommon Stock | 1,606 | $1.58 | $2,540.85 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 6 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · ownership.nature: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | SaleCommon Stock | 1,606 | $1.48 | $2,376.88 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 5 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,606 F2 · ownership.nature: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 26, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | GiftCommon Stock | 2,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 4 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,212 F2 · ownership.nature: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| November 26, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | GiftCommon Stock | 2,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 3 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,206 Read SEC document |
| October 03, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | GiftCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 2 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 604 F2 · ownership.nature: Shares held by Davin Family Nominee Trust u/a 4/16/04 ("Davin Family Trust"), of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Davin Family Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Read SEC document |
| October 03, 2025 Filed Dec 5, 2025 19:23 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | GiftCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-310088 · ownership.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,814 F1 · balance_after: On January 3, 2025, the Issuer effected a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share (the "Reverse Stock Split"). The number of securities reported herein have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 16:51 UTC | ALLURION TECHNOLOGIES, INC. ALUR · Entity 8577 | GrantCommon Stock | 45,235 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-055247 · ownership.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,422 F1 · shares: The shares reported in this transaction represent an initial, one-time grant of Restricted Stock Units ("RSUs") issued pursuant to the Issuer's non-employee director compensation policy and the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in equal annual installments over three years from October 23, 2023, subject to the Reporting Person's continued service as a director of the Issuer on each such vesting date. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerRestricted Stock Units · Derivative | 30,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · derivative · entry 12 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,172 shares Expires 2027-02-08 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6 · price: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerRestricted Stock Units · Derivative | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · derivative · entry 11 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,875 shares Expires 2026-02-10 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6 · price: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerRestricted Stock Units · Derivative | 11,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · derivative · entry 10 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,088 shares Expires 2025-02-11 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cynosure, Inc.'s common stock. F6 · price: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding and unvested restricted stock unit as of immediately prior to the Effective Time vested in full and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 21,108 | Not disclosed Strike: $30.51 | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · derivative · entry 9 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 21,108 shares Expires 2025-02-11 F4 · price: Includes 16,887 shares that were unvested prior to the Effective Time and 4,221 shares that were vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F4 · derivative.exercise_date: Includes 16,887 shares that were unvested prior to the Effective Time and 4,221 shares that were vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerStock Option (right to purchase) · Derivative | 12,062 | Not disclosed Strike: $29.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · derivative · entry 8 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,062 shares Expires 2024-02-13 F3 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. F3 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each outstanding and unexercised stock option as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive, for each underlying share, the difference between the Merger Consideration and the exercise price per share of the option. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerClass A Common Stock | 73,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 7 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | GrantClass A Common Stock | 73,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 6 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,754 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerClass A Common Stock | 62,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 5 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | GrantClass A Common Stock | 62,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 4 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,893 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | Disposition to issuerClass A Common Stock | 58,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 3 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | GrantClass A Common Stock | 58,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 2 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,176 F2 · price: Represents unvested performance-based share units that became vested and were converted in the Merger into the right to receive the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding and unvested performance-based share unit as of immediately prior to the Effective Time vested with respect to the maximum number of shares that could be earned thereunder and was automatically canceled and converted into the right to receive the Merger Consideration for each underlying share. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 16:31 UTC | CYNOSURE INC CYNO · Entity 177540 | OtherClass A Common Stock | 38,625 | $66.00 | $2,549,250.00 |
DisclosureSEC source: 0000899243-17-008505 · doc4.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2017, by and among Hologic, Inc., Minuteman Merger Sub, Inc. and Cynosure, Inc. (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive $66.00 per share, net to the seller in cash, without interest, less any required withholding taxes (the "Merger Consideration"). Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Tax withholdingClass A Common Stock | 2,917 | $65.88 | $192,169.33 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 6 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,625 F5 · shares: On February 13, 2017, 7,881 shares that were acquired by the reporting person pursuant to the award of restricted stock units on February 13, 2014 vested and were paid to the reporting person. On February 14, 2017, 2,917 of these 7,881 shares were withheld and sold in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to pay the resulting tax liability. F6 · price: The sales price reported represents the weighted average sales price of shares sold in multiple transaction at prices ranging from $65.00 to $65.99 per share. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionRestricted Stock Units · Derivative | 7,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · derivative · entry 9 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 7,881 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F10 · derivative.exercise_date: The restricted stock units from the February 13, 2014 award are fully vested as of February 13, 2017. F10 · derivative.expiration_date: The restricted stock units from the February 13, 2014 award are fully vested as of February 13, 2017. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 7,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 5 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Tax withholdingClass A Common Stock | 5,670 | $50.94 | $288,856.45 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 4 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,661 F3 · shares: On February 11, 2017, 11,088 shares that were acquired by the reporting person pursuant to the award of restricted stock units on February 11, 2015 vested and were paid to the reporting person. On February 13, 2017, 5,670 of these 11,088 shares were withheld and sold in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to pay the resulting tax liability. F4 · price: The sales price reported represents the weighted average sales price of shares sold in multiple transaction at prices ranging from $50.00 to $50.99 per share. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Tax withholdingClass A Common Stock | 4,319 | $50.88 | $219,757.63 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 2 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,243 F1 · shares: On February 10, 2017, 8,438 shares that were acquired by the reporting person pursuant to the award of restricted stock units on February 10, 2016 vested and were paid to the reporting person. On February 13, 2017, 4,319 of these 8,438 shares were withheld and sold in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to pay the resulting tax liability. F2 · price: The sales price reported represents the weighted average sales price of shares sold in multiple transaction at prices ranging from $49.00 to $52.99 per share. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 11, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionRestricted Stock Units · Derivative | 11,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · derivative · entry 8 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,088 Underlying: Class A Common Stock · 11,088 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F9 · derivative.exercise_date: The restricted stock units are scheduled to vest as follows: 11,088 shares on February 11, 2018. F9 · derivative.expiration_date: The restricted stock units are scheduled to vest as follows: 11,088 shares on February 11, 2018. Read SEC document |
| February 11, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 11,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 3 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionRestricted Stock Units · Derivative | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · derivative · entry 7 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 Underlying: Class A Common Stock · 8,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F8 · derivative.exercise_date: The restricted stock units are scheduled to vest as follows: 8,438 shares on February 10, 2018 and 8,437 shares on February 10, 2019. F8 · derivative.expiration_date: The restricted stock units are scheduled to vest as follows: 8,438 shares on February 10, 2018 and 8,437 shares on February 10, 2019. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:56 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010719 · doc4.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 15:58 UTC | CYNOSURE INC CYNO · Entity 177540 | GrantRestricted Stock Units · Derivative | 30,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009505 · doc4.xml · derivative · entry 1 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,172 Underlying: Class A Common Stock · 30,172 shares Expires 2027-02-08 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: The restricted stock units are scheduled to vest as to approximately 33% of the shares on each anniversary of the grant date. Read SEC document |
| February 03, 2017 Filed Feb 3, 2017 17:36 UTC | CYNOSURE INC CYNO · Entity 177540 | Tax withholdingClass A Common Stock | 5,111 | $50.10 | $256,060.08 |
DisclosureSEC source: 0001209191-17-007757 · doc4.xml · nonDerivative · entry 2 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,124 F1 · shares: On February 1, 2017, 10,118 shares that were acquired by the reporting person pursuant to the award of the performance-based stock units vested and were paid to the reporting person. On February 3, 2017, 5,111 of these 10,118 shares were withheld and sold in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to pay the resulting tax liability. F2 · price: The sales price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $50.03 to $51.03 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:36 UTC | CYNOSURE INC CYNO · Entity 177540 | GrantClass A Common Stock | 10,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007757 · doc4.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,235 Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,055 | $0.00 Strike: $29.40 | $0.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · derivative · entry 9 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,061 Underlying: Class A Common Stock · 10,055 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable as to approximately 8.33% of the shares on each three-month anniversary of the 2/13/2014 grant date. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | SaleClass A Common Stock | 10,055 | $45.00 | $452,475.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 6 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 10,055 | $29.40 | $295,617.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 5 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,007 | $0.00 Strike: $29.40 | $0.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · derivative · entry 8 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,116 Underlying: Class A Common Stock · 2,007 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable as to approximately 8.33% of the shares on each three-month anniversary of the 2/13/2014 grant date. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,222 | $0.00 Strike: $30.51 | $0.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · derivative · entry 7 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,108 Underlying: Class A Common Stock · 4,222 shares Expires 2025-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable as to approximately 8.33% of the shares on each three-month anniversary of the 2/11/2015 grant date. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | SaleClass A Common Stock | 2,007 | $45.00 | $90,315.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 4 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 2,007 | $29.40 | $59,005.80 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 3 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | SaleClass A Common Stock | 4,222 | $45.00 | $189,990.00 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 2 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:41 UTC | CYNOSURE INC CYNO · Entity 177540 | Exercise / conversionClass A Common Stock | 4,222 | $30.51 | $128,813.22 |
DisclosureSEC source: 0001209191-16-151725 · doc4.xml · nonDerivative · entry 1 Davin Michael R · CIK 0001345975 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.